Fadi Nasr
Overview
Explore the profile of Fadi Nasr including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
211
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tfayli A, Ghanem H, Nasr F, Kourie H, Hachem G, Debs J, et al.
Future Oncol
. 2024 Nov;
21(1):127-137.
PMID: 39545604
Treatment of non-small-cell lung cancers (NSCLC) has evolved over the last decade. According to studies, the use of targeted therapies has significantly increased the life expectancy of patients. Moreover, ALK-tyrosine...
2.
Ayoub G, Sinan H, Kourie H, Kattan J, Nasr F, El Karak F, et al.
Future Oncol
. 2023 Oct;
19(29):1991-2002.
PMID: 37795707
Chronic lymphocytic leukemia (CLL) is a highly heterogenous hemopathy. Genetic stratification of CLL patients has important prognostic and therapeutic values - mainly immunoglobulin heavy chain variable region gene () mutational...
3.
Chalhoub I, Boulos R, Dagher Y, El Helou S, Haifa K, Atallah B, et al.
Medicine (Baltimore)
. 2023 Sep;
102(39):e34562.
PMID: 37773843
Elevated blood levels of low-density lipoprotein cholesterol are a major cardiovascular risk factor, and cholesterol-lowering drugs are among the most prescribed drugs worldwide. Cancer is the second leading cause of...
4.
Dagher Y, El Helou S, Haifa K, Chalhoub I, Boulos R, Atallah B, et al.
Medicine (Baltimore)
. 2023 Sep;
102(36):e34901.
PMID: 37682163
Cardiovascular diseases (CVD) are the leading cause of death globally, followed by cancer. Angiotensin II contributes greatly to CVD pathogenesis, and Angiotensin II receptor blockers (ARBs) constitute a mainstay in...
5.
Kassab J, Nasr L, Gebrael G, Chedid El Helou M, Saba L, Haroun E, et al.
Front Oncol
. 2023 Jun;
13:1176617.
PMID: 37305580
No abstract available.
6.
Abdallah R, Atallah D, Bitar N, Chahine G, Ghanem H, Ghosn M, et al.
Gynecol Oncol Rep
. 2023 May;
47:101186.
PMID: 37181681
Ovarian cancer is the most lethal gynecologic cancer. The high grade serous epithelial (HGSE) subtype is the most aggressive and it often presents at advanced stages, while screening programs have...
7.
Hamadeh L, Farhat L, Hilal L, Assi H, Nasr F, Chahine G, et al.
Gene
. 2023 Apr;
871:147433.
PMID: 37068694
The PIK3CA pathway is one of the most frequently altered pathways in human cancers, especially in breast cancer with approximately 40% of HR+/HER2- advanced breast cancer cases exhibiting mutations in...
8.
Aoun-Bacha Z, Bitar N, Abi Saleh W, Assi H, Bahous J, Boukhalil P, et al.
Oncol Lett
. 2023 Feb;
25(3):113.
PMID: 36844621
Proper management of stage III non-small cell lung cancer (NSCLC) might result in a cure or patient long-term survival. Management should therefore be preceded by adequate and accurate diagnosis and...
9.
Kattan J, El Karak F, Farhat F, Gerges D, Mokaddem W, Chahine G, et al.
BMC Cancer
. 2022 Nov;
22(1):1114.
PMID: 36316658
Background: This study aimed to report the prevalence of HER2-neu in newly diagnosed early or metastatic gastric cancer (GC) patients, to determine the percentage of patients achieving various IHC scores...
10.
Temraz S, Nasr F, Kattan J, Abigerges D, Moukadem W, Farhat F, et al.
Biologics
. 2022 Feb;
16:7-15.
PMID: 35221671
Purpose: When combined with chemotherapy, bevacizumab improves progression-free survival (PFS) in metastatic colorectal cancer (mCRC). This observational trial was designed to assess the safety and efficacy of bevacizumab plus first-line...